Document Detail


Prevention of hepatitis A by Havrix: a review.
MedLine Citation:
PMID:  16117704     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hepatitis A is one of the most common vaccine-preventable infectious diseases in the world. With at least 1.5 million cases of hepatitis A worldwide each year, disease management constitutes a substantial economic burden. The first effective vaccine against hepatitis A, Havrix was introduced in 1992. This review summarizes data accumulated following more than a decade of clinical experience with this vaccine and compares clinical data with other currently available hepatitis A vaccines. Based on this data and on the current immunological knowledge, a recent consensus concluded that hepatitis A vaccines induce lifelong protection, and thus booster vaccinations against hepatitis A are unnecessary in fully immunized, healthy people. In view of this, current regulatory recommendations for the use of hepatitis A vaccines are reviewed and possible future strategies identified.
Authors:
Koen Van Herck; Pierre Van Damme
Related Documents :
7875094 - Hepatitis b virus infection among blood donors and pregnant women in maiduguri, nigeria.
9730294 - Immune thrombocytopenic purpura after recombinant hepatitis b vaccine: retrospective st...
11075984 - Guillain - barre' syndrome following recombinant hepatitis b vaccine and literature rev...
9951594 - Solitary mastocytoma arising at a hepatitis b vaccination site.
1520764 - Chronic arthritis after rubella vaccination.
15978534 - Immunisation in the current management of cystic fibrosis patients.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of vaccines     Volume:  4     ISSN:  1744-8395     ISO Abbreviation:  Expert Rev Vaccines     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-08-24     Completed Date:  2006-06-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101155475     Medline TA:  Expert Rev Vaccines     Country:  England    
Other Details:
Languages:  eng     Pagination:  459-71     Citation Subset:  IM    
Affiliation:
Centre for the Evaluation of Vaccination, WHO Collaborating Centre for the Prevention and Control of Viral Hepatitis, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium. koen.vanherck@ua.ac.be
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Hepatitis A / immunology,  prevention & control*
Hepatitis A Vaccines / administration & dosage*,  immunology
Hepatitis A Virus, Human / drug effects*,  immunology
Humans
Vaccines, Inactivated / administration & dosage,  immunology
Chemical
Reg. No./Substance:
0/Hepatitis A Vaccines; 0/Vaccines, Inactivated

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in ...
Next Document:  Prospects for a T-cell receptor vaccination against myasthenia gravis.